Illumina Names Dr. Robert S. Epstein to its Board of Directors

  Illumina Names Dr. Robert S. Epstein to its Board of Directors

Business Wire

SAN DIEGO -- November 29, 2012

Illumina, Inc. (NASDAQ: ILMN) today announced that Dr. Robert S. Epstein,
M.D., has joined the company’s Board of Directors. Dr. Epstein is an
epidemiologist who worked in public health and academia before joining the
private sector.

Previously, from 2010 to 2012, Dr. Epstein was Chief R&D Officer and President
of Medco-UBC, a 2,400 person global research organization focused on
conducting personalized medicine, health economics, drug safety, outcomes, and
comparative effectiveness research on behalf of the biopharmaceutical, medical
device, and diagnostics industries. Prior to this role, Dr. Epstein was
Medco’s Chief Medical Officer for 13 years, where he led formulary
development, clinical guideline development, drug information services,
personalized medicine program development, and client analytics and reporting.
In addition, Dr. Epstein is the former President of the International Society
of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the
board of directors of the Drug Information Association (DIA) and the
International Society of Quality of Life. Dr. Epstein has published more than
75 peer-reviewed medical articles and book chapters and serves as a reviewer
for several influential medical journals, including the New England Journal of
Medicine and JAMA.

“We are delighted to welcome Rob to the Illumina Board, and excited by the
prospect of working with this dynamic leader to advance personalized
medicine,” said Jay Flatley, Illumina’s President and CEO. “Benefiting from
Rob’s perspective and expertise, at this critical time when scientific and
technological advances in genetic research and biomedicine are beginning to
transform healthcare, will be invaluable as Illumina pursues its clinical
diagnostic growth strategy.”

About Illumina

Illumina ( is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.


Illumina, Inc.
Rebecca Chambers
Investor Relations
Jennifer Temple
Public Relations
Press spacebar to pause and continue. Press esc to stop.